In conclusion, our presented data establish the therapeutic efficacy of a novel combination treatment that targets the PI3K/AKT/mTOR signaling pathway in high-risk B-ALL in Hispanic/Latino children. Here, MTOR is linked to acute lymphoblastic leukemia.